Diagnostics In Brief
This article was originally published in The Gray Sheet
Executive Summary
Pathwork tumor test: Molecular diagnostic firm receives FDA clearance July 29 for its Pathwork Tissue of Origin Test, used to determine the origin of hard-to-identify tumors. The test uses an Affymetrix microarray, cleared along with the tumor test, to measure the uncertain tumor's gene expression pattern and compare it to a panel of 15 known tumor types, including bladder, breast and colorectal. Pathwork is finalizing details to make the IVD kit available later this year; the test is already available as a service through the firm's lab. The test is the second in vitro diagnostic multivariate index assay (IVDMIA) cleared by FDA, after Agendia's MammaPrint breast cancer recurrence test
You may also be interested in...
People In Brief
C-suite changes at Pathwork Diagnostics, Sanuwave Health and BD. More people news.
Guidance Pending To Help Clinical Labs Comply With FDA Manufacturing Regs
FDA is developing guidance for clinical laboratories on how to comply with the device manufacturing quality system regulation
Guidance Pending To Help Clinical Labs Comply With FDA Manufacturing Regs
FDA is developing guidance for clinical laboratories on how to comply with the device manufacturing quality system regulation